CNTX Stock Summary and Trading Ideas (Context Therapeutics | NASDAQ:CNTX)

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

Context Therapeutics trades on the NASDAQ stock market under the symbol CNTX.

As of September 4, 2026, CNTX stock price was flat at $0.36 with 959,378 million shares trading.

CNTX has a beta of -0.23, meaning it tends to be less sensitive to market movements. CNTX has a correlation of 0.00 to the broad based SPY ETF.

CNTX has a market cap of $33.23 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, CNTX traded as high as $3.62 and as low as $.35.

The top ETF exchange traded funds that CNTX belongs to (by Net Assets): VTI, VTWO, IWO, VXF, VTWG.

CNTX has underperformed the market in the last year with a price return of -57.1% while the SPY ETF gained +20.8%. CNTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -82.4% and -30.4%, respectively, while the SPY returned +2.4% and +1.0%, respectively.

CNTX support price is $.34 and resistance is $.38 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CNTX shares will trade within this expected range on the day.